T-acute lymphoblastic leukemia/lymphoma (T-ALL/ LBL) is an aggressive neoplasm derived from T-cell progenitors that represents B15 and 25% of all ALL/LBL cases in children and adults, respectively. The disease can initially present as lymphoblastic lymphoma (T-LBL) involving thymus, nodal, and extranodal sites, and/or as acute lymphoblastic leukemia (T-ALL) involving primarily peripheral blood and bone marrow. The outcome of patients with T-ALL/LBL has been significantly improved with intensified chemotherapy. Complete remission can be achieved initially in over 90% of T-ALL/LBL patients, but a substantial subset of patients eventually develop relapsed disease. The 5-year overall survival for patients with T-ALL/LBL is over 80% in children 1 and B50% in adults, [2] [3] [4] [5] with most relapses occurring within 2 years after initial remission. 4 Patients with relapsed T-ALL/LBL usually respond poorly to augmented salvage chemotherapy and allogeneic hematopoietic stem cell transplant. 4, 6 The key to improve survival therefore is to identify patients at high risk for relapse at the time of initial diagnosis and to implement risk-adapted therapy.
Immunophenotyping is essential in the diagnostic workup of T-ALL/LBL. Lymphoblasts express cytoplasmic CD3 and other T-lineage makers as well as one or more markers of immaturity, including CD34, CD1a, and terminal deoxynucleotidyl transferase (TdT). The latter is normally expressed in T-(and B-) cell precursors and is a marker expressed in 95% of cases of ALL/LBL by flow cytometry. 7, 8 TdTnegative T-ALL/LBL has not been reported in a large study, but occasional case reports of TdT-negative T-ALL/LBL can be found in the literature. [9] [10] [11] [12] In patients who had T-ALL/LBL without TdT expression, response to vincristine and prednisone therapy was poor. 9, 10 A recent study has shown that TdT expression in T-ALL/LBL can be gradually downregulated in up to 90% of cases of T-ALL/LBL following induction chemotherapy, at the time of detection of minimal residual disease (MRD). 13 This finding suggests that therapy modulates TdT expression, either by promoting maturation of neoplastic cells or by selecting preexistent TdTnegative cells. As MRD at the end of induction is one of the most significant risk factors for predicting relapse and adverse outcome in patients with T-ALL/LBL, [14] [15] [16] [17] diminished or absent TdT expression may be a marker of chemoresistance. This finding, along with the few case reports of TdT-negative T-ALL/LBL with poor prognosis, therefore prompted us to query if negative/low TdT in T-ALL/LBL is associated with an adverse outcome to frontline chemotherapy.
Two recent studies have shown that a subset of T-ALL/LBL cases with an immunophenotype considered to be of an early T-precursor origin, 'early T precursor' (ETP), belongs to a very high risk group. The ETP immunophenotype is described as lack of CD1a and CD8, CD5-/dim þ , and expression of one or more myeloid or stem cell-related antigens. 18, 19 Both studies focused on pediatric patients and did not further specify whether TdTnegative T-ALL/LBL cases fall into the ETP type of T-ALL/LBL.
In this single institution study of de novo T-ALL/ LBL, we identified a group of patients with TdTnegative T-ALL/LBL and compared their clinical presentation, immunophenotype, karyotype, and outcome to a group of patients with TdT-positive T-ALL/LBL. We also explored the potential overlap between TdT-negative T-ALL/LBL and T-ALL/LBL cases with an ETP immunophenotype.
Materials and methods

Study Group
We reviewed available data on de novo T-ALL/LBL patients who were diagnosed and treated at our hospital between 2003 and 2011. All T-ALL/LBL cases expressed cytoplasmic CD3 (cCD3) and completely lacked myeloperoxidase (MPO) activity assessed by cytochemical analysis on peripheral blood or bone marrow smears. Cases of mixed T-/myeloid acute leukemia were excluded. The distinction between T-ALL and T-LBL was made based on clinical and pathology findings. T-ALL was defined as presenting primarily as leukemia, with or without concurrent extramedullary involvement, whereas T-LBL was defined primarily as an extramedullary disease with o25% lymphoblasts in blood or bone marrow. All patients in the study group were treated with frontline chemotherapy including hyperfractionated cyclophosphamide, vincristine, daunorubicin (Adriamycin), and dexamethasone (modified hyper-CVAD), or augmented Berlin-Frankfurt-Munster therapy for younger patients, with or without nelarabine and central nervous system (CNS) prophylaxis. Patients with mediastinal disease at presentation received radiation therapy for consolidation. Patients who developed relapsed disease were treated with various augmented salvage chemotherapy regimens, and allogeneic stem cell transplant in a subset. T-ALL/ LBL patients with relapsed disease referred to our hospital for salvage treatment were excluded. This study was approved by the MDACC institutional review board; written informed consents were obtained in accordance with the Declaration of Helsinki Principles.
Flow Cytometry Immunophenotyping
As part of the routine diagnostic workup, multicolor flow cytometric immunophenotypic analysis was performed on cell suspensions of fresh tissue and/or bone marrow aspirate samples collected in EDTA. After incubation of cells with monoclonal antibodies for 10 min at 4 1C, erythrocytes were lysed with NH 4 Cl for 10 min, followed by two washing steps using phosphate-buffered saline solution. The cells were resuspended and fixed with 1% paraformaldehyde. A panel of markers, including CD1a, CD2, CD3, cytoplasmic CD3, CD4, CD5, CD7, CD8, CD10, CD13, CD33, CD34, CD45, CD56, CD117, MPO, TdT, and HLA-DR, were used. All antibodies were obtained from BD Biosciences (San Jose, CA, USA), except anti-CD10 obtained from Beckman Coulter (Brea, CA, USA) and anti-TdT was obtained from Supertechs (Rockville, MD, USA). The analyses were performed using FACScan, FACSCaliber, or FACSCanto flow cytometers (BD).
TdT Immunoreactivity
TdT immunoreactivity was determined by flow cytometry immunophenotyping (FCI) of fresh tissue biopsy specimens or bone marrow aspirate specimens and/or by immunohistochemical (IHC) analysis of formalin-fixed and paraffin-embedded tissue sections. For FCI analysis, TdT immunoreactivity was determined by comparing TdT-specific monoclonal antibody (FITC, Cat# 6100, Supertechs) to its isotype control and internal negative control. For IHC staining, rabbit anti-TdT polyclonal antibody (1:20, DAKO, Denmark) was used on biopsy Negative TdT in T-lymphoblastic leukemia/lymphoma Y Zhou et al sections. TdT-negative cases were defined as TdT expression in o10% of T lymphoblasts by IHC and FCI studies, as previously recommended. 20 All TdTnegative cases identified by FCI were confirmed by IHC staining.
Statistical Analysis
Descriptive statistics were presented for demographic and clinical characteristics. Categorical measures were summarized using frequencies and percentages and assessed using Fisher's exact tests. Continuous measures were summarized using medians and ranges and assessed using Kruskal-Wallis tests. Progression of disease and overall survival were estimated using Kaplan-Meier survival curves and the log-rank test was used to assess differences between the groups. A multivariate Cox proportional hazards regression model was fit to determine the association between progression of disease and age, gender, initial disease site, white blood cell (WBC) count, CNS involvement, ETP immunophenotype status, and TdT status. A similar model was fit for overall survival. All statistical tests used a significance level of 5%. All statistical analyses were performed using SAS 9.3 for Windows (Copyright 2011 by SAS Institute, Cary, NC, USA).
Results
The study included 59 patients with de novo T-ALL/ LBL from 2003 to 2011. There were 41 males (69%) and 18 females (31%) with a median age of 31 years (range, 2-77 years). In all, 22 (37%) patients presented initially with only leukemia, 20 (34%) patients presented with leukemia but also had extramedullary involvement, and 17 (29%) patients presented primarily with T-LBL. Together, 37 (63%) patients demonstrated extramedullary disease. The median WBC count among patients who presented with leukemia was 12.1 Â 10 9 /l (range 0.4-241 Â 10 9 /l). Twelve (20%) patients presented with a WBC count 4100 Â 10 9 /l and 10 (19%) Negative TdT in T-lymphoblastic leukemia/lymphoma patients had CNS involvement at the time of initial diagnosis.
TdT-Negative T-ALL/LBL
TdT expression was assessed by flow cytometry and/or IHC. The level of TdT expression varied among different cases and within each tumor. Of the 59 cases, 7 (12%) cases displayed nearly uniform absence of TdT expression, confirmed by IHC staining (Figure 1 ). There were 4 males and 3 females with a median age of 47 years (range, 13-76 years). Two patients presented with a WBC count 4100 Â 10 9 /l and one patient had CNS involvement at the time of initial diagnosis. Three of five cases (60%) analyzed successfully by conventional cytogenetics had an abnormal karyotype. There were no significant differences with regard to gender, site of involvement, frequency of a high leukocyte count (4100 Â 10 9 /l), and an abnormal karyotype between patients with TdT-negative versus TdT-positive T-ALL/LBL. The median age for the TdT-negative cases was higher compared with the positive cases, but this difference was not statistically significant (Table 1) .
T-ALL/LBL with an ETP Immunophenotype
Nine (16%) of 57 analyzed cases with sufficient immunophenotypic data for assessment had an ETP immunophenotype. These cases were uniformly negative for CD1a and CD8 and uniformly positive for cCD3 and CD7; CD5 was partially positive in o50% of neoplastic cells in all cases; other markers were variably positive, including CD2 (3 of 9 cases, 33%), sCD3 (1 of 9 cases, 11%), CD10 (1 of 8 cases, 12%), CD34 (6 of 9 cases, 67%), CD117 (2 of 7 cases, 29%), CD13 (2 of 6 cases, 33%), CD33 (6 of 7 cases, 86%), HLA-DR (3 of 9 cases, 33%), and TdT (6 of 9 cases, 67%). There were 6 males and 3 females with a median age of 36 years (range, 19-66 years). Two (22%) patients presented with WBC count 4100 Â 10 9 /l and two patients had CNS involvement at initial diagnosis. Cytogenetic analysis showed an abnormal karyotype in 5 (83%) of 6 cases. There were no significant differences in age, gender, site, initial WBC count, and abnormal karyotype between cases with or without an ETP phenotype ( Table 1 ). The TdTnegative cases (3 of 7; 43%) were more likely to have an ETP phenotype than TdT-positive cases (6 of 50; 12%; P ¼ 0.07), but this difference was not statistically significant (Table 1) . (Table 2 ) and a shorter overall survival (Table 3 ; Figure 2 ). The 3-year cumulative frequency of progression was 39% in the study cohort, but 92% in patients with WBC 4100 Â 10 9 /l, 76% in patients with CNS involvement, 87% in cases with an ETP phenotype, or 86% in negative TdT cases. The 3-year overall survival was 61% in the study cohort, but 19% in patients with WBC 4100 Â 10 9 /l, 28% in patients with CNS involvement, 13% in cases with an ETP phenotype and 0% in negative TdT cases. In a multivariate analysis that included age, WBC 4100 Â 10 9 /l, CNS involvement, ETP phenotype, and absence of TdT, negative TdT remained a significant independent risk factor predicting disease progression (P ¼ 0.0001; Table 2 ) and shorter overall survival (Table 3) . We further analyzed the clinical outcome of the seven pediatric patients aged r18 years. Among them, 2 had TdT-negative T-ALL/LBL, and none had an ETP phenotype. Of the 7 patients, 2 relapsed: one was a 2-year-old patient with TdT-positive T-ALL and the other a 15-year-old patient with TdT-negative T-ALL/ LBL. Thus, in this limited pediatric group, 1 of 2 (50%) patients with TdT-negative T-ALL relapsed, as compared with 1 out of 5 (20%) patients with TdT-positive T-ALL/LBL. In comparison, 5 of 52 adult patients had TdT-negative T-ALL/LBL; all 5 (100%) patients relapsed within 12 months of achieving remission.
Discussion
In this study, the most notable difference between TdT-negative and TdT-positive T-ALL/LBL was the poorer outcome, association with an ETP immunophenotype, and more advanced age seen in the TdTnegative subgroup. The frequency of TdT-negative cases in this study, 7 of 59 (12%), is comparable with 10% reported previously. 8, 13, 21, 22 The patients in this study were treated either with augmented Berlin-Frankfurt-Munster regimen for younger patients or hyper-CVAD±nelarabine regimen for older patients. Overall, 27 of 59 (46%) patients had one or more risk factors of poor prognosis: 20% had a WBC count 4100 Â 10 9 /l, 19% had CNS involvement, 16% had a neoplasm with an ETP immunophenotype, and 12% had TdT-negative T-ALL/LBL. Each of these features was significantly associated with a higher risk of relapse and shorter overall survival, but the highest risk was associated with an ETP and TdT-negative immunophenotype.
Part of the high risk observed in TdT-negative ALL/LBL can be attributable to ETP. TdT-negative T-ALL/LBL cases were more likely to have an ETP immunophenotype than TdT-positive cases, 43 versus 12%, respectively, although not statistically significant in this small cohort (P ¼ 0.07). Early studies have shown that patients with T-ALL/LBL showing a prethymic T-cell immunophenotype, that is, cytoplasmic CD3 þ , CD7 þ , surface CD3 À , CD1a À , CD4 À , and CD8 À , have a significantly shorter overall survival than other subgroups. 23, 24 The concept of an ETP immunophenotype has been recently validated and refined by gene expression profiling. 19 The ETP immunophenotype is characterized by lack of CD1a and CD8 expression, negative or weak CD5 expression, and expression of one or more myeloid or stem cell markers, including CD117, CD34, HLA-DR, CD13, CD33, CD11b, and/or CD65. ETP-positive cases represent B5-13% of T-ALL/LBL in pediatric patients and are a very high risk group. 19 Our study showed in adult patients that 16% of de novo cases had an ETP immunophenotype and these patients were at significantly higher risk. However, ETP immunophenotype did not account for all cases of TdTnegative T-ALL/LBL in this study, as absence of TdT expression remained significant in the multivariate analysis that included other known risk factors such as WBC 4100 Â 10 9 /L, CNS involvement, and the ETP immunophenotype, 25 indicating that TdT expression is an independent risk factor.
Additional risk factors in T-ALL/LBL, including mutation and aberrant expression of TLX3, 26 BAALC and ERG, 27 and WT1, 28, 29 have been preferentially observed in cases with an ETP immunophenotype. These genes regulate development of hematopoietic stem cells and are implicated in adverse prognosis of both acute myeloid leukemia (AML) and ALL. [30] [31] [32] It is possible that high expression of ERG, BAALC, or WT1 signifies stem cell-like properties that protect these tumors against chemotherapy. In fact, T-ALL/ LBL with an ETP immunophenotype has a genetic profile more akin to normal hematopoietic and myeloid leukemic stem cells 33 and may carry FLT3-ITD mutation, a feature typically associated with AML. 34 TdT is normally expressed in committed T-lymphocytic progenitors. 35 TdT-negative T-ALL/LBL may be derived from an early stage of T precursors simply lacking TdT expression or from a later stage of precursors with a perturbed T-cell differentiation. For the TdT-negative T-ALL/LBL without the ETP profile, it is possible that the tumor cells may acquired stem cell properties.
From a practical point of view, the use of TdT as a prognostic marker in patients with T-ALL/LBL has two advantages. First, TdT is widely tested during the initial diagnostic workup of T-ALL/LBL. Second, TdT is an independent risk factor. These features make TdT readily applicable in the clinical setting. T-ALL/LBL is a rare disease and TdTnegative cases represent only a small subset (B12%). A multicenter study may be worthwhile to further confirm the prognostic value of TdT expression in risk stratification of T-ALL/LBL patients. Our study suggests that patients with TdT-negative T-ALL/LBL belong to a high risk group who may benefit from allogeneic stem cell transplant at the first complete remission.
